NeuroPace to Report Third Quarter 2026 Financial Results on November 12, 2026
NeuroPace (Nasdaq: NPCE) will report third-quarter 2026 financial results after market close on November 12, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Investors interested in listening to the conference call may do so by accessing a live webcast of the event here. Individuals interested in participating in the call via telephone may access the call by dialing +1 833-461-5787 and referencing Conference ID 345 741 415. The webcast will be archived on the company’s investor relations website at https://investors.neuropace.com/news-and-events/events and will be available for replay for at least 90 days after the event.
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261029382681/en/
Investor Contact:
Scott Schaper
Head of Investor Relations
sschaper@neuropace.com
investors@neuropace.com
Source: NeuroPace, Inc.